Neurocrine Biosciences has published a comprehensive review in CNS Spectrums, detailing over a decade of clinical research on VMAT2 inhibitors, particularly INGREZZA. The review emphasizes INGREZZA's unique efficacy, including selective VMAT2 targeting and simplified dosing, which can aid healthcare providers in treatment decisions.
The review presents robust clinical data showing significant efficacy and favorable tolerability of INGREZZA in treating tardive dyskinesia, especially at the lowest available dose of 40 mg. This information is crucial for clinicians as it highlights the importance of drug selection based on each medication's unique mechanism and safety profile.
As Neurocrine's stock rises by 5.90%, this positive sentiment around INGREZZA's clinical data and its implications for treatment decisions may be contributing to the stock's performance, alongside broader market gains.
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 179.68 USD with a low forecast of 143.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 179.68 USD with a low forecast of 143.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 134.660
Low
143.00
Averages
179.68
High
203.00
Current: 134.660
Low
143.00
Averages
179.68
High
203.00
UBS
Buy
downgrade
$188 -> $178
2026-01-23
Reason
UBS
Price Target
$188 -> $178
AI Analysis
2026-01-23
downgrade
Buy
Reason
UBS lowered the firm's price target on Neurocrine to $178 from $188 and keeps a Buy rating on the shares. Crenessity momentum could break the stock out of its historical range, the analyst tells investors in a research note.
Truist
Buy
maintain
$172 -> $169
2026-01-08
Reason
Truist
Price Target
$172 -> $169
2026-01-08
maintain
Buy
Reason
Truist lowered the firm's price target on Neurocrine to $169 from $172 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NBIX
Unlock Now
Morgan Stanley
Overweight -> Equal Weight
downgrade
$173 -> $175
2026-01-08
Reason
Morgan Stanley
Price Target
$173 -> $175
2026-01-08
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Neurocrine to Equal Weight from Overweight with a price target of $175, up from $173. The firm sees Neurocrine facing several potential headwinds over the coming year and with limited clinical catalysts until 2027, the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$168 -> $198
2025-12-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$168 -> $198
2025-12-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Neurocrine to $198 from $168 and keeps a Buy rating on the shares following the research and development day. The company "redefined its growth trajectory" by unveiling NBIP-2118, an obesity candidate that leverages CRF2 biology to preserve lean muscle, "offering a distinct competitive advantage over existing incretins," the analyst tells investors in a research note. The firm believes the Neurocrine's "high risk-reward move" is balanced by its "de-risked" neuropsychiatry pipeline.
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
